Anti-CD38 monoclonal antibodies represent an important advance in the treatment of multiple myeloma, providing new effective options for patients with newly diagnosed and relapsed/refractory disease.
Role of CD38 Antibodies in Multiple Myeloma
Anti-CD38 monoclonal antibodies represent an important advance in the treatment of multiple myeloma, providing new effective options for patients with newly diagnosed and relapsed/refractory disease.